Read about Endologix
in the news

Embrace the evidence.

The Latest:

One-Year Results of the DETOUR2 Trial published in the Journal of Vascular Surgery (JVS)

See Release

2023 News

Archives

Endologix Announces that Lucas Buchanan Joins Board of Directors

Endologix Announces First Patients Treated with the DETOUR™ System, Advancing Treatment for Complex Peripheral Artery Disease

Endologix Announces 24-Month Results of DETOUR- 2 Study at 2023 Vascular Annual Meeting

Endologix receives FDA Approval of the DETOUR™ System to Treat Long Complex Superficial Femoropopliteal Lesions in Patients with PAD.

Endologix Announces 150th Patient Enrolled in JAGUAR Randomized Controlled Trial